Martine van Vugt
Director/Board Member at SCANDION ONCOLOGY A/S
Martine van Vugt active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 2023-03-28 | - |
| Human Resources Officer | 2018-12-31 | 2023-03-28 | |
| TME PHARMA N.V. | Director/Board Member | 2021-06-23 | - |
| Independent Dir/Board Member | 2021-06-23 | - | |
| SCANDION ONCOLOGY A/S | Director/Board Member | 2022-03-31 | - |
| Independent Dir/Board Member | 2022-03-31 | - | |
Immagene BV
 Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Director/Board Member | - | - |
| Hollandbio | Director/Board Member | - | - |
Career history of Martine van Vugt
Training of Martine van Vugt
| University of Utrecht | Doctorate Degree |
| Wageningen University | Graduate Degree |
Statistics
International
| Netherlands | 5 |
| Denmark | 3 |
| Germany | 2 |
Operational
| Director/Board Member | 4 |
| Independent Dir/Board Member | 2 |
| Human Resources Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GENMAB A/S | Health Technology |
| TME PHARMA N.V. | Health Technology |
| SCANDION ONCOLOGY A/S | Health Technology |
| Private companies | 2 |
|---|---|
| Hollandbio | |
Immagene BV
Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Martine van Vugt
- Experience
